Breast Cancer Clinical Trial

19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction

Summary

Six female patients (>18 years of age, pre-menopausal) who have had loco-regional (lumpectomy and radiation) therapy for breast carcinoma and have been at least one-year disease free will undergo liposuction, the autologous SVF cell fraction will be isolated and labeled with CS-1000 in the operating room without entering cell culture, which will then be returned to the patient at the site of breast grafting. Patients will receive a pre-screening MRI . Patients will have an MRI scans over a period of 1 month at Johns Hopkins. Follow-up MRIs at 6,12, and 18 months will also be performed. Only at Johns Hopkins with fluorine being done as part of this investigational study. By performing fluorine MRI and quantification of 19F signal, we hypothesize that the engraftment of transplanted cells can be tracked in ways not possible before, using the total fluorine signal as surrogate marker for cell persistence and survival. We expect that a clinically successful outcome (maintenance of breast contour and volume) will be positively correlated with cell survival. The outcome of this study may pave the way for using 19F MRI cell tracking as a new tool for stem cell therapy in a variety of clinical applications.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient capable and willing to sign the Informed Consent (see attached document)
Patient must be willing to complete all visits in this study
Female, >18 years of age
Lumpectomy and radiation therapy for breast carcinoma
18 month disease free survival
No evidence of metastatic disease
Patient is fit for surgery as determined by preoperative medical clearance workup performed by an independent primary care physician.
Negative pregnancy test.

Exclusion Criteria:

Evidence of metastatic disease
Less than 18 months disease-free interval
Unable to undergo MRI:

3a) Metallic implant 3b) Claustrophobic 4) High risk for surgical intervention because of comorbidities 5) Received treatment with an investigational drug within 30 days of screening.

Study is for people with:

Breast Cancer

Phase:

Phase 1

Study ID:

NCT02035085

Recruitment Status:

Withdrawn

Sponsor:

Johns Hopkins University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

CosmeticSurg
Lutherville-Timonium Maryland, 21093, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Study ID:

NCT02035085

Recruitment Status:

Withdrawn

Sponsor:


Johns Hopkins University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider